Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: A phase II, open-label, multicenter, randomized study.
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2013
At a glance
- Drugs Nimotuzumab (Primary) ; Carboplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jun 2013 New trial record
- 31 May 2013 Primary endpoint 'Objective-clinical-response-rate' has been met.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.